CAG
62
-2
PVH
28
-5
WHR
40
-3
NOV
44
-4
MRK
53
-5
SYK
40
-4
EXPE
40
-2
CPB
69
-3
ORLY
58
-3
R
49
-3
PFE
23
-15
ECL
42
-8
JNPR
56
-4
URI
56
-6
IR
41
-5
NFLX
39
-3
EMR
57
-3
KMI
48
-5
TDC
36
-13
PCG
77
-3
CAG
62
-2
PVH
28
-5
WHR
40
-3
NOV
44
-4
MRK
53
-5
SYK
40
-4
EXPE
40
-2
CPB
69
-3
ORLY
58
-3
R
49
-3
PFE
23
-15
ECL
42
-8
JNPR
56
-4
URI
56
-6
IR
41
-5
NFLX
39
-3
EMR
57
-3
KMI
48
-5
TDC
36
-13
PCG
77
-3
Financhill
Back

NovoCure Quote, Financials, Valuation and Earnings

Is it possible to have a crash proof portfolio?

See important Reg A disclosures: Masterworks.com/cd
Sell
44

NVCR
NovoCure

Last Price:
57.10
Seasonality Move:
31.19%

7 Day Trial

ALL ACCESS PASS

$ 7

Ready For A Once In A Generation Opportunity In The Copper Space?

Click for more info and ADD THIS COMPANY TO YOUR WATCHLIST!

NovoCure Price Quote

$57.10

NovoCure Key Stats

Sell
44
NovoCure (NVCR) is a Sell
Day range:
$56.52 - $60.42
52-week range:
$56.39 - $120.03
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
11.11
P/B ratio:
13.65%
Volume:
1.5M
Avg. volume:
649.8K
1-year change:
-25.63%
Market cap:
$6B
Revenue:
$537.8M
EPS:
$-0.88

How Much Does NovoCure Make?

  • How Much Are NovoCure's Sales Annually?
    NVCR Revenues are $537.8M
  • How Much Profit Does NovoCure's Make A Year?
    NVCR net income is -$92.5M

Is NovoCure Growing As A Company?

  • What Is NovoCure's Growth Rate Quarterly?
    Quarterly YoY revenue growth is -0.04%
  • What Is NovoCure's EPS Quarterly YoY Growth Rate?
    Quarterly, year-over-year diluted EPS growth rate is 0%

NovoCure Stock Price Performance

  • Did NovoCure Stock Go Up Last Month?
    NovoCure share price went down by -32.62% last month
  • Did NVCR's Share Price Rise Over The Last Year?
    NVCR share price fell by -25.63% over the past 1 year

What Is NovoCure 52-Week High & Low?

  • What Is NovoCure’s 52-Week High Share Price?
    NovoCure has traded as high as $120.03 over the past 52 weeks
  • What Is NovoCure’s 52-Week Low Share Price?
    NovoCure has traded as low as $56.39 over the past 52 weeks

NovoCure Price To Free Cash Flow

  • Is NovoCure Stock Overvalued?
    NovoCure is trading at a price to free cash flow ratio of 633.79
  • Is NovoCure Stock Undervalued?
    NovoCure EV to Free Cash Flow ratio is 595.71
  • What Is NovoCure’s Price Earnings Growth Ratio?
    NVCR PEG ratio is -1.14
  • Is NovoCure Trading At A Premium To Earnings?
    NovoCure EV to EBIT ratio is 0.00

Is It Risky To Buy NovoCure?

  • How Much Debt Does NovoCure Have?
    Total long term debt quarterly is $565.5M
  • How Much Cash Does NovoCure Have?
    Cash and short term investments quarterly total is $969.4M
  • What Is NovoCure’s Book Value Per Share?
    Book value per share is 4.20

Is NovoCure Cash Flow Positive?

  • What Is NVCR Cash Flow From Operations?
    Cash flow from operations (TTM) is $30.8M
  • What Is NovoCure’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $15.5M
  • What Is NovoCure’s Cash Flow From Investing?
    Cash flow from investing (TTM) is -$140M

NovoCure Return On Invested Capital

  • Is Management Doing A Good Job?
    NVCR return on invested capital is -9.27%
  • What Is NovoCure Return On Assets?
    ROA measures how assets are converting to revenues and is -7.95%
  • What Is NVCR Return On Equity?
    ROE is a measure of profitability and is -21.28%

NovoCure Earnings Date & Stock Price

  • What Is NovoCure's Stock Price Today?
    A single share of NVCR can be purchased today for 57.10
  • What Is NovoCure’s Stock Symbol?
    NovoCure trades on the nasdaq under the ticker symbol: NVCR
  • When Is NovoCure’s Next Earnings Date?
    The next quarterly earnings date for NovoCure is scheduled on April 28, 2023
  • When Is NVCR's next ex-dividend date?
    NovoCure's next ex-dividend date is March 20, 2023
  • How To Buy NovoCure Stock?
    You can buy NovoCure shares by opening an account at a top tier brokerage firm, such as TD Ameritrade or tastyworks.

NovoCure Competitors

  • Who Are NovoCure's Competitors?
    Below is a list of companies who compete with NovoCure or are related in some way:
    • Boston Scientific Corp (BSX)
    • Perspective Therapeutics Inc (CATX)
    • NeuroMetrix Inc (NURO)
    • Insulet Corp (PODD)
    • Teleflex Inc (TFX)

NovoCure Dividend Yield

Data Unavailable

NovoCure Analyst Estimates

YoY Growth Past Surprise
EPS: 0% -15.31%
Revenue: -3.59% 0.76%

Analyst Recommendations

Buy Recommendations: 2
Hold Recommendations: 2
Sell Recommendations: 2
Price Target: 96.75
Upside from Last Price: 69.44%

Major Shareholders

  • How many NVCR shares are owned by institutional investors?
    170.7M NVCR shares are owned by institutional investors
  • How many NVCR shares are owned by insiders?
    8.1M NVCR shares are owned by insiders